person · Reporting owner

MCLAUGHLIN KEVIN F

Disclosed activity across 4 companies

Tapewire entity: 23536
SEC CIK: 0001214938

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Invivyd, Inc.IVVD · Entity 721	Director	May 19, 2026	May 21, 2026
Vericel CorpVCEL · Entity 4481	Director	August 12, 2026	August 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Invivyd, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2036-05-18	Direct	50,000	Reported balance After 2026-05-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-19 · Grant · Acquired 50,000 · Balance 50,000 F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Vericel Corp

Report date August 12, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,300	Ending reported balance After 2026-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-12 · Exercise / conversion · Acquired 7,000 · Balance 25,300 Row 2 · 2026-08-12 · Sale · Disposed 7,000 · Balance 18,300 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2028-05-02	Direct	7,000	Reported balance After 2026-08-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-12 · Exercise / conversion · Acquired 7,000 · Balance 7,000 F2: These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.

F2: These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACCELERON PHARMA INC

Report date November 19, 2021 · Filed November 22, 2021

Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-11-19 transaction · row 1 1 source row Row 1 · 2021-11-19 · Other · Disposed 10,681 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $30.17	Direct	Reported balance After 2021-11-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-19 · Disposition to issuer · Disposed 2,663 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.61	Direct	Reported balance After 2021-11-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-11-19 · Disposition to issuer · Disposed 11,262 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64	Direct	Reported balance After 2021-11-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-11-19 · Disposition to issuer · Disposed 20,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99	Direct	Reported balance After 2021-11-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-11-19 · Disposition to issuer · Disposed 24,334 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53	Direct	Reported balance After 2021-11-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-11-19 · Disposition to issuer · Disposed 18,806 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

Decibel Therapeutics, Inc.

Report date September 25, 2023 · Filed September 25, 2023

Section 16 reporting ended · disclosed 2023-09-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-09-25 transaction · row 1 1 source row Row 1 · 2023-09-25 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3: Includes 5,000 unvested Company RSUs.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.88 · Expires 2032-10-09	Direct	Reported balance After 2023-09-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-25 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.78 · Expires 2033-06-12	Direct	Reported balance After 2023-09-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-25 · Disposition to issuer · Disposed 5,000 · Balance 0 F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"),

F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU.

F3: Includes 5,000 unvested Company RSUs.

F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time.

F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 08, 2020 Filed Apr 10, 2020 17:29 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	10,000	$27.97	$279,700.00	Disclosure SEC source: 0001179110-20-004829 · edgar.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 08, 2020 Filed Apr 10, 2020 17:29 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	12,774	$41.20	$526,288.80	Disclosure SEC source: 0001179110-20-004829 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 08, 2020 Filed Apr 10, 2020 17:29 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	4,000	$24.11	$96,440.00	Disclosure SEC source: 0001179110-20-004829 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 22, 2020 Filed Jan 24, 2020 17:21 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	24,334	$0.00 Strike: $52.99	$0.00	Disclosure SEC source: 0001179110-20-000767 · edgar.xml · derivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,334 Underlying: Common Stock · 24,334 shares Expires 2030-01-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2020. Read SEC document
January 22, 2020 Filed Jan 24, 2020 17:21 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	6,369	$0.00	$0.00	Disclosure SEC source: 0001179110-20-000767 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,216 Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:41 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,566	$52.52	$82,246.32	Disclosure SEC source: 0001179110-20-000272 · edgar.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,847 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.13 to $52.92 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:41 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	2,300	$52.49	$120,727.00	Disclosure SEC source: 0001179110-20-000272 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,413 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.08 to $52.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:41 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,713	$52.51	$89,949.63	Disclosure SEC source: 0001179110-20-000272 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,713 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
December 13, 2019 Filed Dec 17, 2019 18:39 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	11,853	$50.28	$595,968.84	Disclosure SEC source: 0001179110-19-012954 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,426 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.74 to $50.51 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
September 10, 2019 Filed Sep 10, 2019 20:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	173	$45.75	$7,914.75	Disclosure SEC source: 0001179110-19-010220 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,279 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.74 to $45.76 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
September 10, 2019 Filed Sep 10, 2019 20:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	7,827	$45.29	$354,484.83	Disclosure SEC source: 0001179110-19-010220 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,452 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.73 to $45.71 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
May 01, 2019 Filed May 3, 2019 20:09 UTC	Vericel Corp VCEL · Entity 4481	GrantRestricted Stock Unit · Derivative	1,750	$0.00	$0.00	Disclosure SEC source: 0001593968-19-001037 · primary_01.xml · derivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2020 or the date of the first Annual Meeting of Stockholders following May 1, 2019. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document
May 01, 2019 Filed May 3, 2019 20:09 UTC	Vericel Corp VCEL · Entity 4481	GrantStock Option (right to buy) · Derivative	13,125	$0.00 Strike: $16.62	$0.00	Disclosure SEC source: 0001593968-19-001037 · primary_01.xml · derivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 13,125 shares Expires 2029-05-01 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document
April 09, 2019 Filed Apr 11, 2019 16:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	100	$45.46	$4,546.00	Disclosure SEC source: 0001179110-19-004911 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,279 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 09, 2019 Filed Apr 11, 2019 16:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	11,900	$44.61	$530,859.00	Disclosure SEC source: 0001179110-19-004911 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,379 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $44.93 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
April 02, 2019 Filed Apr 4, 2019 18:07 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	648	$48.02	$31,116.96	Disclosure SEC source: 0001179110-19-004790 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,279 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.03 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
January 25, 2019 Filed Jan 29, 2019 17:38 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	28,000	$0.00 Strike: $41.64	$0.00	Disclosure SEC source: 0001179110-19-001053 · edgar.xml · derivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2029-01-25 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2019. Read SEC document
January 25, 2019 Filed Jan 29, 2019 17:38 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	4,700	$0.00	$0.00	Disclosure SEC source: 0001179110-19-001053 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,927 Read SEC document
January 02, 2019 Filed Jan 4, 2019 18:34 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	97	$44.06	$4,273.82	Disclosure SEC source: 0001179110-19-000468 · edgar.xml · nonDerivative · entry 5 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,227 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 02, 2019 Filed Jan 4, 2019 18:34 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,717	$43.33	$74,397.61	Disclosure SEC source: 0001179110-19-000468 · edgar.xml · nonDerivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,324 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.88 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document
January 02, 2019 Filed Jan 4, 2019 18:34 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	2,186	$42.56	$93,036.16	Disclosure SEC source: 0001179110-19-000468 · edgar.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,041 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.98 to $42.97 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
January 02, 2019 Filed Jan 4, 2019 18:34 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	300	$43.20	$12,960.00	Disclosure SEC source: 0001179110-19-000468 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,227 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.15 to $43.29 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
January 02, 2019 Filed Jan 4, 2019 18:34 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,412	$42.37	$59,826.44	Disclosure SEC source: 0001179110-19-000468 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,527 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.89 to $42.88 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
August 30, 2018 Filed Aug 31, 2018 19:00 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	12,500	$0.00 Strike: $27.97	$0.00	Disclosure SEC source: 0001179110-18-011049 · edgar.xml · derivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,300 Underlying: Common Stock · 12,500 shares Expires 2026-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. Read SEC document
August 30, 2018 Filed Aug 31, 2018 19:00 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	12,500	$54.00	$675,000.00	Disclosure SEC source: 0001179110-18-011049 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,939 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
August 30, 2018 Filed Aug 31, 2018 19:00 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	12,500	$27.97	$349,625.00	Disclosure SEC source: 0001179110-18-011049 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
June 29, 2018 Filed Jul 3, 2018 14:32 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	25,000	$0.00 Strike: $24.11	$0.00	Disclosure SEC source: 0001179110-18-009302 · edgar.xml · derivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 25,000 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. Read SEC document
June 29, 2018 Filed Jul 3, 2018 14:32 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	12,500	$49.00	$612,500.00	Disclosure SEC source: 0001179110-18-009302 · edgar.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,939 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
June 29, 2018 Filed Jul 3, 2018 14:32 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	12,500	$47.00	$587,500.00	Disclosure SEC source: 0001179110-18-009302 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,439 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
June 29, 2018 Filed Jul 3, 2018 14:32 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	25,000	$24.11	$602,750.00	Disclosure SEC source: 0001179110-18-009302 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
May 02, 2018 Filed May 3, 2018 19:29 UTC	Vericel Corp VCEL · Entity 4481	GrantStock Option (right to buy) · Derivative	17,500	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001593968-18-000734 · primary_01.xml · derivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-05-02 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company Read SEC document
April 03, 2018 Filed Apr 4, 2018 16:38 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	800	$39.00	$31,200.00	Disclosure SEC source: 0001179110-18-005396 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,939 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.87 to $39.20 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
April 03, 2018 Filed Apr 4, 2018 16:38 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	3,200	$38.31	$122,592.00	Disclosure SEC source: 0001179110-18-005396 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,739 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.84 to $38.71 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:14 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	30,825	$0.00 Strike: $40.61	$0.00	Disclosure SEC source: 0001179110-18-003494 · edgar.xml · derivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,825 Underlying: Common Stock · 30,825 shares Expires 2028-03-01 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018. Read SEC document
March 01, 2018 Filed Mar 5, 2018 17:14 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	5,138	$0.00	$0.00	Disclosure SEC source: 0001179110-18-003494 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,939 Read SEC document
January 04, 2018 Filed Jan 4, 2018 19:03 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	200	$43.84	$8,768.00	Disclosure SEC source: 0001179110-18-000546 · edgar.xml · nonDerivative · entry 5 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,801 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.79 to $43.90 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
January 04, 2018 Filed Jan 4, 2018 19:03 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	14,800	$43.00	$636,400.00	Disclosure SEC source: 0001179110-18-000546 · edgar.xml · nonDerivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,001 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.74 to $43.64 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
January 03, 2018 Filed Jan 4, 2018 19:03 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	6,250	$0.00 Strike: $5.28	$0.00	Disclosure SEC source: 0001179110-18-000546 · edgar.xml · derivative · entry 7 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. Read SEC document
January 03, 2018 Filed Jan 4, 2018 19:03 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	6,251	$0.00 Strike: $3.88	$0.00	Disclosure SEC source: 0001179110-18-000546 · edgar.xml · derivative · entry 6 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,251 shares Expires 2020-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter. Read SEC document
January 03, 2018 Filed Jan 4, 2018 19:03 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	6,250	$5.28	$33,000.00	Disclosure SEC source: 0001179110-18-000546 · edgar.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2018 Filed Jan 4, 2018 19:03 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	6,251	$3.88	$24,253.88	Disclosure SEC source: 0001179110-18-000546 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 02, 2018 Filed Jan 4, 2018 19:03 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	4,000	$42.42	$169,680.00	Disclosure SEC source: 0001179110-18-000546 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,300 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $42.83 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
September 12, 2017 Filed Sep 14, 2017 17:02 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	210	$39.85	$8,368.50	Disclosure SEC source: 0001179110-17-012287 · edgar.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,300 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.82 to $39.96 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
September 12, 2017 Filed Sep 14, 2017 17:02 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,300	$39.17	$50,921.00	Disclosure SEC source: 0001179110-17-012287 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,510 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.78 to $39.75 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
September 12, 2017 Filed Sep 14, 2017 17:02 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	14,490	$38.32	$555,256.80	Disclosure SEC source: 0001179110-17-012287 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,810 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.75 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
July 05, 2017 Filed Jul 7, 2017 16:55 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	18,750	$0.00 Strike: $7.12	$0.00	Disclosure SEC source: 0001179110-17-010226 · edgar.xml · derivative · entry 5 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2022-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. Read SEC document
July 05, 2017 Filed Jul 7, 2017 16:55 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	3,150	$0.00 Strike: $5.28	$0.00	Disclosure SEC source: 0001179110-17-010226 · edgar.xml · derivative · entry 4 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 3,150 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. Read SEC document
July 05, 2017 Filed Jul 7, 2017 16:55 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	34,400	$32.00	$1,100,800.00	Disclosure SEC source: 0001179110-17-010226 · edgar.xml · nonDerivative · entry 3 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,300 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 05, 2017 Filed Jul 7, 2017 16:55 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	18,750	$7.12	$133,500.00	Disclosure SEC source: 0001179110-17-010226 · edgar.xml · nonDerivative · entry 2 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 05, 2017 Filed Jul 7, 2017 16:55 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	3,150	$5.28	$16,632.00	Disclosure SEC source: 0001179110-17-010226 · edgar.xml · nonDerivative · entry 1 MCLAUGHLIN KEVIN F · CIK 0001214938 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.